SCHEMBL792560

SCHEMBL792560

Cc1ccc2c(C3CCCCC3)c3n(c2c1)CCN(CC(=O)N1CCSCC1)c1ccccc1-3

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 3/20 0.39
CHRM4 P08173 3/20 0.39
CHRM1 P11229 3/20 0.39
CHRM3 P20309 3/20 0.39
PRKCA P17252 1/20 0.36
MMP12 P39900 1/20 0.36
MAPT P10636 4/20 0.35
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
HIF1A Q16665 1/20 0.34
SAE1 Q9UBE0 1/20 0.34
UBA2 Q9UBT2 1/20 0.34
NR1I2 O75469 1/20 0.34
F10 P00742 2/20 0.34
CCKBR P32239 4/20 0.33
SCN9A Q15858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL804122 0.89 PRKCA (0.46) CHRM2CHRM4CHRM1CHRM3PRKCA
SCHEMBL14572857 0.88 PRKCA (0.39) CHRM2CHRM4CHRM1CHRM3PRKCA
SCHEMBL792424 0.87 PRKCA (0.41) PRKCAMMP12MAPTLMNAKDM4E
SCHEMBL804162 0.86 PRKCA (0.34) CHRM2CHRM4CHRM1CHRM3PRKCA
SCHEMBL792637 0.86 PRKCA (0.33) CHRM2CHRM4CHRM1CHRM3PRKCA
SCHEMBL792562 0.84 PRKCA (0.33) PRKCAMMP12MAPTKDM4EALDH1A1
SCHEMBL792173 0.82 PRKCA (0.37) PRKCAMMP12MAPTKDM4EALDH1A1
SCHEMBL804154 0.82 PRKCA (0.48) CHRM2CHRM4CHRM1CHRM3PRKCA
SCHEMBL10283571 0.82 PRKCA (0.48) CHRM2CHRM4CHRM1CHRM3PRKCA
SCHEMBL10283570 0.82 PRKCA (0.48) CHRM2CHRM4CHRM1CHRM3PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 CHRM2 4885/4885CHRM4 4878/4885CHRM1 4876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.